Pro-Dex, Inc. (PDEX)

Pro-Dex, Inc. stock has experienced notable events in the past six months. In May 2025, despite reporting a record performance for Q3 2025, the stock crashed 32%. In July 2025, the stock saw an 8.2% jump. In August 2025, Wall Street Zen lowered its rating on Pro-Dex from a "buy" to a "hold". In September 2025, Pro-Dex reported Q4 2025 earnings of $0.36 per share, missing the Zacks Consensus Estimate. In October 2025, Weiss Ratings reiterated a "hold (C+)" rating for Pro-Dex. The stock has been volatile over the past year, and its weekly volatility has been stable but remains higher than 75% of US stocks.

Demand for some of Pro-Dex's core medical device products may be relatively resilient to broader economic fluctuations, implying a less pronounced seasonality compared to other industries. The available information does not indicate significant seasonal fluctuations in demand for Pro-Dex's products and services.

Pro-Dex, Inc. is an engineering and manufacturing company specializing in precision medical devices and components, operating primarily within the Medical sector, specifically in the Medical Equipment & Supplies and Medical Instruments industries. Founded in 1978 and headquartered in Irvine, California, Pro-Dex designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) worldwide. Its major products include autoclavable, battery-powered, and electric multi-function surgical drivers and shavers, primarily utilized in orthopedic, thoracic, and craniomaxillofacial surgeries. Pro-Dex also offers high-performance dental handpieces and components, as well as precision components for industrial and aerospace applications. Beyond manufacturing, the company provides engineering, quality, and regulatory consulting services and is increasingly developing its own proprietary technology and products.

Pro-Dex, Inc. sells its powered surgical instruments to medical device OEMs worldwide. The company's corporate headquarters and manufacturing facilities are located in Irvine, California, with an additional facility in Tustin, California. Pro-Dex offers its outsourcing services "nationwide and beyond." Its products are found in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations globally.

Pro-Dex, Inc. generally holds a "Moderate Buy" consensus rating from analysts. In February 2025, Pro-Dex received an upgrade to a Zacks Rank #1 (Strong Buy). In August 2025, Wall Street Zen downgraded the stock from a "buy" to a "hold" rating. In October 2025, Weiss Ratings reiterated a "hold (C+)" rating. The company's stock underperformed the US Medical Equipment industry and the broader US Market over the past year.

Institutional investors and hedge funds collectively own 15.28% of Pro-Dex, Inc.'s stock, with notable investors including Bank of New York Mellon Corp, Navellier & Associates Inc., American Century Companies Inc., Cubist Systematic Strategies LLC, Jane Street Group LLC, BlackRock, Inc., Vanguard Group Inc., Dimensional Fund Advisors LP, Northern Trust Corp., and Geode Capital Management, LLC. Insiders own 23.92% of the company's shares.